Olopatadine

RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis (SAR), now available across Canada

Retrieved on: 
Wednesday, May 3, 2023

"The launch of this new therapy adds to our broad portfolio of treatments that further establishes Bausch Health as a trusted partner in the healthcare of Canadians."

Key Points: 
  • "The launch of this new therapy adds to our broad portfolio of treatments that further establishes Bausch Health as a trusted partner in the healthcare of Canadians."
  • "Allergic rhinitis is a common disorder that often doesn't respond adequately to usual treatments" said Dr. Paul Keith, Professor, Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University.
  • "Nasal congestion, nasal itch, runny nose and sneezing are classic symptoms of the disorder.
  • The onset of action for nasal symptom relief occurs within 15 minutes after administration of RYALTRIS.1

Alcon to Debut TOTAL30 for Astigmatism, Dry Eye and Ocular Health Innovations at SECO 2023

Retrieved on: 
Wednesday, March 1, 2023

Alcon will debut TOTAL30® for Astigmatism, the first and only reusable Water Gradient toric lens on the market,1 now available to Eye Care Professionals (ECPs) across the U.S.

Key Points: 
  • Alcon will debut TOTAL30® for Astigmatism, the first and only reusable Water Gradient toric lens on the market,1 now available to Eye Care Professionals (ECPs) across the U.S.
  • In addition to showcasing its latest innovations, Alcon will present its newest clinical data and research findings across its vision care, dry eye, allergy and ocular health portfolios.
  • “Alcon is thrilled to be celebrating 100 years of SECO,” said Sean Clark, General Manager, U.S.
  • Visit Alcon booth #1138 for refreshments, samples of SYSTANE HYDRATION PF, Pataday, and TOTAL30 for Astigmatism, and literature on Alcon’s products.

Pharmaceutical Drugs Global Market Report 2022: Skyrocketing Chronic Disease Rates Boosting Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022

The "Pharmaceutical Drugs Global Market Report 2022: By Type, By Distribution, By Route, By Drug, By Mode" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical Drugs Global Market Report 2022: By Type, By Distribution, By Route, By Drug, By Mode" report has been added to ResearchAndMarkets.com's offering.
  • North America was the largest region in the pharmaceutical drugs market in 2021.
  • The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • These factors are expected to increase the patient pool globally, thereby driving the pharmaceutical drugs market during the forecast period.

Football Star Cooper Kupp Encourages Eye Allergy Sufferers to Find the Right Tool for the Job with Pataday

Retrieved on: 
Monday, June 6, 2022

This years campaign, The Right Tool for the Job, highlights Kupps personal struggle to find the right product to treat his eye allergy symptoms and how Pataday has delivered fast-acting, long-lasting, and targeted relief for his itchy allergy eyes on and off the field.

Key Points: 
  • This years campaign, The Right Tool for the Job, highlights Kupps personal struggle to find the right product to treat his eye allergy symptoms and how Pataday has delivered fast-acting, long-lasting, and targeted relief for his itchy allergy eyes on and off the field.
  • I use PatadayOnce Daily Relief Extra Strength because it puts me in control of my allergy symptoms and its efficient.
  • With just one drop in each eye, I love that I can count on 24 hours of relief from itchy eyes.
  • Approximately 66 million Americans suffer from ocular allergies, but only 9 million use an over-the-counter allergy eye drop to relieve their symptoms.4-7 Through this campaign, we hope to encourage eye allergy sufferers to find targeted, fast-acting relief from their eye allergy symptoms.

Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray in Singapore, Hong Kong and Vietnam

Retrieved on: 
Thursday, January 20, 2022

Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris, while Lotus International Pte.

Key Points: 
  • Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris, while Lotus International Pte.
  • MUMBAI, India, Jan. 20, 2022 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven, global, integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Lotus International Pte.
  • Ltd., a wholly owned subsidiary of Lotus Pharmaceutical Co., Ltd. (Lotus), for commercializing its innovative nasal sprayRyaltrisinSingapore, Hong Kong and Vietnam.
  • Glenmark will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus.

Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age an

Retrieved on: 
Friday, January 14, 2022

"With this NDA approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms."

Key Points: 
  • "With this NDA approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms."
  • Ryaltris is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray approved by the FDA for the treatment of symptoms associated with Seasonal Allergic Rhinitis.
  • The combination drug product nasal spray is indicated for the treatment of symptoms associated with seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older.
  • The safety and effectiveness of Ryaltris in pediatric patients younger than 12 years of age has not been established.

Dr. Reddy’s announces the launch of Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalent of Pataday®, the Eye Allergy Drop in the U.S. Market

Retrieved on: 
Thursday, September 17, 2020

Dr. Reddys Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.

Key Points: 
  • Dr. Reddys Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.
  • The Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% is also indicated for the temporary relief of red eyes.
  • We are very excited to extend our strategic collaboration with Gland Pharma to bring these products to the market.
  • Dr. Reddys Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% is available in a 2.5 mL bottle and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% is available in a 5 mL bottle size.

Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength

Retrieved on: 
Tuesday, July 14, 2020

With Pataday Once Daily Relief Extra Strength, eye allergy sufferers will get over-the-counter eye allergy itch relief that lasts a full 24 hours.

Key Points: 
  • With Pataday Once Daily Relief Extra Strength, eye allergy sufferers will get over-the-counter eye allergy itch relief that lasts a full 24 hours.
  • This formulation joins Pataday Once Daily Relief (olopatadine hydrochloride ophthalmic solution 0.2%) and Pataday Twice Daily Relief (olopatadine hydrochloride ophthalmic solution 0.1%), which were approved for sale over-the-counter in February 2020.
  • Both Pataday Twice Daily Relief and Pataday Once Daily Relief are available now in all major food, drug and mass retailers nationally.
  • Pataday Once Daily Relief Extra Strength will be available online beginning in September, ahead of national retail availability in February 2021.

Alcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch

Retrieved on: 
Monday, February 17, 2020

The rights to the Rx-to-OTC switch were secured by Alcon as part of its separation from Novartis in April 2019.

Key Points: 
  • The rights to the Rx-to-OTC switch were secured by Alcon as part of its separation from Novartis in April 2019.
  • Alcon will market both Patanol Solution (olopatadine 0.1%) and Pataday Solution (olopatadine 0.2%) under the Pataday brand name as Pataday Twice Daily Relief and Pataday Once Daily Relief, respectively.
  • My hope is that more allergy sufferers will discover the benefits of Pataday and add it to their medicine cabinet this spring allergy season and beyond.
  • The launch is supported by a multimillion-dollar media plan including a national TV advertising campaign and strong online presence to reach eye allergy sufferers.